Browsing by Author "Karadaǧ, Mehmet"
Now showing 1 - 3 of 3
- Results Per Page
- Sort Options
Item Mutation analysis of the FHIT gene in bronchoscopic specimens from patients with suspected lung cancer(Sage Publications, 2008) Çeçener, Gülşah; Tunca, Berrin; Egeli, Ünal; Karadaǧ, Mehmet; Vatan, Özgür; Uzaslan, Esra Kunt; Tolunay, Şahsine; Uludağ Üniversitesi/Fen-Edebiyat Fakültesi/Biyoloji Bölümü.; Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Biyoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı.; 0000-0001-7904-883X; 0000-0002-3820-424X; 0000-0002-9027-1132; 0000-0002-7687-3284; 0000-0002-1619-6680; AAH-1420-2021; AAP-9988-2020; AAG-8744-2021; AAI-1612-2021; O-7508-2015; ABI-6078-2020; ISV-0209-2023; 6508156530; 6602965754; 55665145000; 6601970351; 16235098100; 8761653500; 6602604390Aims and background. Lung cancer is a leading cause of cancer death worldwide. However, despite recent advances in molecular biology that have revealed various genetic changes in lung cancer, the prognostic Outcome of lung cancer patients has improved only minimally. This Situation has changed fundamentally With the identification of molecular abnormalities that are characteristic of premalignant changes, Such as changes ill tumor suppressor genes, loss of heterozygosity at crucial sites, and activation of oncogenes. Inactivation of the tumor suppressor gene Fragile Histidine Triad (FHIT) is a frequent genetic change in lung cancer. The aim of this study was to identify FHIT-gene alterations in bronchoscopy specimens of patients with suspected lung cancer and to determine the molecular relevance, if any, of FHIT alterations in the development of cancer.Patients and methods. Sixty-two patients with suspected lung tumors were screened for variations within exons 5-9 of the FHIT gene using intronic primer pairs and single-strand conformation polymorphism and sequencing analysis.Results. FHIT gene alterations were detected in 27 out of 62 bronchoscopic specimens (43.54%). All of these alterations were identified as T to A alteration at position IVS8-17. This intronic variant also was identified in approximately half of control cases (45%).Conclusions. Our findings showed that the FHIT IVS8-17 T to A alteration identified in bronchoscopy specimens from patients with clinically suspected lung cancer is a polymorphism found in the Turkish population. We think that this polymorphism does not affect gene function because it is located in the intron portion of the gene and is present in many cancer patients as well as healthy Subjects. We Suggest that the FHIT gene may be turned off in lung carcinogenesis via other genetic or epigenetic mechanisms rather than mutations.Item Neutrophil-to-lymphocyte ratio in obstructive sleep apnea; a multi center, retrospective study(Verduci Publisher, 2015-09) Altıntaş, Nejat; Yüceege, Melike Bağnu; Fırat, Hikmet; Çetinoğlu, Ezgi Demirdöğen; Acet, A. N.; Ursavaş, Ahmet; Karadaǧ, Mehmet; Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları Anabilim Dalı.; 0000-0002-9027-1132; AAI-3169-2021; AAG-8744-2021; 57189524206; 57212943552; 8329319900; 6601970351OBJECTIVE: Systemic inflammation is important in pathophysiology of obstructive sleep apnea (OSA) and its comorbidity. Neutrophil to lymphocyte ratio (N/L ratio) is a novel inflammation index that has been shown to independently predict poor clinical outcomes. In this study, we aimed to evaluate the role of N/L ratio in OSA patients and comparing with other well-known inflammatory marker, C-reactive protein (CRP). PATIENTS AND METHODS: We conducted a retrospective analysis of 481 patients with mild, moderate and severe OSA (163,158 and 160 patients, respectively) and leukocyte profiles of 80 sex-, age-and body mass index-matched healthy controls. Patients were excluded if they had underlying cancer, chronic inflammatory disease, any systemic infection, uncontrolled hypertension and diabetes mellitus, a known acute coronary syndrome, valvular heart disease, a known thyroid, renal or hepatic dysfunction. RESULTS: We found that N/L Ratio in severe OSA patients was significantly higher compared with mild, moderate, OSA patients and healthy controls (p < 0.001). However, there was no difference between mild and moderate OSA patients (p = 0.636). There was also no significant difference between mild-moderate OSA patients and healthy groups (p = 0.150). CRP levels were not different in all OSA stages (p = 0.595). By Spearman correlation, there was no correlation between CRP and N/L ratio. CONCLUSIONS: N/L ratio, which is quick, cheap, easily measurable novel inflammatory marker with routine complete blood count analysis, is a surrogate marker of obstructive sleep apnea severity.Item Soluble vascular endothelial growth factor receptor-1 (sVEGFR-1) is decreased in lung cancer patients showing progression: A pilot study(Taylor & Francis, 2007) Yağcı, Artay; Sevimli, Alper; Akgöz, Semra; Yılmaztepe, Arzu O.; Ulukaya, Engin; Zık, Berrin; Yılmaz, Meryem; Erdoğan, Beril Bahadır; Koç, Melike; Tokullugil, Asuman Hatice; Karadaǧ, Mehmet; Uludağ Üniversitesi/Tıp Fakültesi/Biyokimya Anabilim Dalı.; Uludağ Üniversitesi/Veteriner Fakültesi/Histoloji ve Embriyoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları ve Verem Anabilim Dalı.; 0000-0002-9027-1132; 0000-0003-0463-6818; AAG-8744-2021; K-5792-2018; A-5841-2017; 8606136100; 6602927353; 6507763192; 57197051873; 8833423500; 13906271900; 6507662010; 6601970351Tumor growth and metastasis depend on angiogenesis, and the vascular endothelial growth factor (VEGF) is known to be one of the most important angiogenic factors although the knowledge about its receptors is limited. We, therefore, investigated the treatment-related changes both in the level of the soluble vascular endothelial growth factor receptor-1 ( sVEGFR-1) in the serum by ELISA and the expression of VEGFR-1 in cancer tissues by immunohistochemistry. The serum levels were studied in 38 lung cancer patients, and 55 control subjects ( 21 benign disease and 34 healthy subjects) before the chemotherapy. The treatment-related changes in serum sVEGFR-1 were evaluated in 15 patients 24 and 48 hours after treatment. In addition to serum analysis, the tissue expressions were evaluated in 32 patients before treatment. The treatment-related changes in tissue VEGFR-1 expressions were evaluated in only 12 patients 24 hours after treatment. We observed no significant difference in terms of serum sVEGFR-1 levels between malignant and nonmalignant groups (p > 0.05). There were no significant differences in the levels of sVEGFR-1 before and after treatment (p > 0.05). However, there was a significant difference between sVEGFR-1 levels in the groups (regressive, stable, progressive) classified according to the response to therapy (p = 0.043). A significant difference also was present between the expression levels of tissue VEGFR-1 in the same groups (p = 0.037). As a conclusion, we suggest that prechemotherapy sVEGFR- 1 can be helpful for prediction of long-term response to therapy, but it should be studied in larger groups to elucidate its benefit in clinics.